In the four ESCC cells, the combination of gefitinib and linsitinib could not only significantly reduce the activation of EGFR, HER2, IGF-1R, AKT, and ERK, but it also had a stronger inhibitory effect than any single drugs. This evidence concerns the gene ERBB2 and esophageal squamous cell carcinoma.